Crealta Pharmaceuticals LLC, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for rare diseases. Founded in 2013, the company has made significant strides in developing treatments that address unmet medical needs, particularly in the areas of pain management and rare conditions. Crealta's flagship product, Krystexxa, is a unique enzyme therapy designed for chronic gout patients who are refractory to conventional treatments. This product has positioned Crealta as a leader in the gout treatment market, showcasing the company's commitment to improving patient outcomes through advanced biopharmaceutical solutions. With a focus on research and development, Crealta continues to expand its portfolio, solidifying its reputation as a trusted name in the healthcare sector.
We don't have data for Crealta Pharmaceuticals LLC, but we can show you information about their parent organization instead.
View parent company